References
- Chu CM , Cheng VCC , Hung IFN , et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.
- De Wilde AH , Jochmans D , Posthuma CC , et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875–4884.
- Kim UJ , Won EJ , Kee SJ , et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21:455–459.
- Cao B , Wang Y , Wen D , et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020. DOI:10.1056/NEJMoa2001282.
- Yao -T-T , Qian J-D , Zhu W-Y , et al. Asystematic review of lopinavir therapy for SARSA coronavirus and MERS coronavirus – a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92:556-63.
- McCoy E. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18(6):1075–1078.
- ClinicalTrials.gov . Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers (COVIDAXIS). [ cited 2020 May 5]. Available from https://clinicaltrials.gov/ct2/show/NCT04328285?term=lopinavir&cond=covid-19&draw=2&rank=4
- ClinicalTrials.gov . Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID-19). [ cited 2020 Apr 30]. Available from https://clinicaltrials.gov/ct2/show/NCT04307693?term=lopinavir&cond=Covid-19&draw=2&rank=1
- Bauman JL , Tisdale JE. Chloroquine and Hydroxychloroquine in the Era of SARS – coV2: caution on Their Cardiac Toxicity. [Epub ahead of print] Pharmacotherapy. 2020;40(5):387–388.
- ClinicalTrials.gov . Trial of early therapies during non-hospitalized outpatient window for COVID-19 (TREAT NOW). [ cited 2020 May 5]. Available from https://clinicaltrials.gov/ct2/show/NCT04372628?term=lopinavir&cond=covid-19&draw=2&rank=5
- World Health Organization . Solidarity clinical trial for COVID-19 treatments. [ cited 2020 Apr 30]. Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
- ClinicalTrials.gov . a prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia. [cited 2020 May 5 ]. Available from https://clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir&cond=covid-19&draw=2&rank=9
- ClinicalTrials.gov . Umifenovir in hospitalized COVID-19 patients (UAIIC). [cited 2020 May 5 ]. Available from https://clinicaltrials.gov/ct2/show/NCT04350684?term=lopinavir&cond=covid-19&draw=2&rank=7
- ClinicalTrials.gov . The clinical study of carrimycin in treated patients with COVID19. [cited 2020 May 6 ]. Available from https://clinicaltrials.gov/ct2/show/NCT04286503
- ClinicalTrials.gov . Clinical trial to evaluate efficacy of 3 types of treatment in patients with pneumonia by COVID-19 (Covid-19HUF). [cited 2020 Apr 30 ]. Available from https://clinicaltrials.gov/ct2/show/NCT04346147?term=lopinavir&cond=Covid-19&draw=2&rank=3
- Beck BR , Shin B , Choi Y , et al. Prediction commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020. DOI:10.1016/j.csbj.2020.03.025
- ClinicalTrials.gov . Effectiveness and safety of medical treatment for SARS-CoV-2 (COVID-19) in Columbia. [cited 2020 May 5 ]. Available from https://clinicaltrials.gov/ct2/show/NCT04359095?term=lopinavir&cond=covid-19&draw=2&rank=6